<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41623" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chlordiazepoxide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahwazi</surname>
            <given-names>Hoda H.</given-names>
          </name>
          <aff>Ross University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hoda Ahwazi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41623.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Chlordiazepoxide&#x000a0;belongs to the category of long-acting benzodiazepines and is approved by the US Food and Drug Administration (FDA) for the management of mild-to-severe anxiety, preoperative anxiety, and alcohol withdrawal in adults.&#x000a0;Although chlordiazepoxide was synthesized and developed in 1956, it was approved for use in 1960. The drug is considered one of the&#x000a0;safest&#x000a0;and most effective benzodiazepine composites among psychopharmacological compounds.&#x000a0;In addition, this medication is FDA-approved for anxiety in pediatric patients aged 6 and older.</p>
        <p>A profound understanding of the complex pharmacology of chlordiazepoxide enables healthcare professionals to formulate personalized treatment plans tailored to individual&#x000a0;patient needs. This in-depth knowledge facilitates informed decision-making in prescribing chlordiazepoxide, optimizing dosage regimens, and minimizing the risk of potential adverse reactions.&#x000a0;This&#x000a0;activity outlines the indications, mechanism of action, administration methods, adverse effects, contraindications, toxicity, and monitoring of chlordiazepoxide in the management of anxiety disorders. Clinicians can utilize this information to guide patient therapy, where indicated, as part of the interprofessional healthcare team. Such expertise is essential for enhancing patient outcomes, particularly in the management of conditions where chlordiazepoxide is crucial in therapeutic interventions, such as anxiety and alcohol withdrawal.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for chlordiazepoxide, recognizing its FDA-approved uses for mild-to-severe anxiety, preoperative anxiety, and alcohol withdrawal in adults.</p></list-item><list-item><p>Implement personalized treatment plans using chlordiazepoxide, considering individual patient needs and optimizing dosage regimens while adhering to recommended guidelines.</p></list-item><list-item><p>Select appropriate candidates for chlordiazepoxide therapy, taking into account age-specific considerations, especially for pediatric patients aged 6 and older.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team, sharing insights and coordinating care plans to optimize patient outcomes while utilizing chlordiazepoxide in anxiety and alcohol withdrawal management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41623&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41623">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41623.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Chlordiazepoxide&#x000a0;belongs to the category of long-acting benzodiazepines and&#x000a0;is considered one of the&#x000a0;safest&#x000a0;and most effective benzodiazepine composites among psychopharmacological compounds. This drug&#x000a0;is approved by the US Food and Drug Administration (FDA) for the management of mild-to-severe anxiety, preoperative apprehension and anxiety, and alcohol withdrawal symptoms in adults.&#x000a0;Although chlordiazepoxide was synthesized and developed in 1956, it was approved for use in 1960.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Chlordiazepoxide is an FDA-approved medication used for treating mild-to-severe anxiety disorder, preoperative apprehension and anxiety, and withdrawal symptoms of acute alcohol use disorder in adults. In addition,&#x000a0;chlordiazepoxide is FDA-approved for anxiety management in pediatric patients aged 6 and older. The American Society of Addiction Medicine (ASAM) recommends front-loading therapy for alcohol withdrawal management. This strategy involves administering a moderate-to-high dose of a long-acting benzodiazepine to rapidly control withdrawal signs and symptoms.</p>
        <p>Front-loading therapy&#x000a0;is specifically advised for patients experiencing severe alcohol withdrawal, indicated by a Clinical Institute Withdrawal Assessment of Alcohol-A revised (CIWA-Ar) score of &#x02265;19. Chlordiazepoxide and diazepam are the preferred agents for implementing front-loading therapy. According to ASAM, chlordiazepoxide, lorazepam, and diazepam are the most frequently used benzodiazepines in alcohol withdrawal.<xref ref-type="bibr" rid="article-41623.r1">[1]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Similar to other medications within the benzodiazepine class, chlordiazepoxide functions as an augmenting agent when used alongside antipsychotics, mood stabilizers, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors in the treatment of psychotic, bipolar, and anxiety disorders. Notably, clinicians need to avoid&#x000a0;combining chlordiazepoxide with other benzodiazepines.<xref ref-type="bibr" rid="article-41623.r2">[2]</xref><xref ref-type="bibr" rid="article-41623.r3">[3]</xref><xref ref-type="bibr" rid="article-41623.r4">[4]</xref></p>
      </sec>
      <sec id="article-41623.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Chlordiazepoxide has anti-anxiety, sedative, appetite-stimulating, and myorelaxant actions.&#x000a0;The medication binds to benzodiazepine receptors at the gamma-aminobutyric acid type A (GABA-A) ligand-gated chloride channel complex and enhances GABA's inhibitory effects. Chlordiazepoxide increases the frequency of chloride opening through GABA-regulated channels.<xref ref-type="bibr" rid="article-41623.r5">[5]</xref>&#x000a0;The therapeutic benefits of anxiety disorder&#x000a0;occur from the inhibition of neuronal activity in amygdala-centered fear circuits.<xref ref-type="bibr" rid="article-41623.r6">[6]</xref><xref ref-type="bibr" rid="article-41623.r7">[7]</xref>&#x000a0;Additionally, it blocks electroencephalogram (EEG) arousal of the reticular formation.<xref ref-type="bibr" rid="article-41623.r8">[8]</xref>&#x000a0;Observing some immediate relief of anxiety symptoms with the first dosing is common, but several weeks with regular dosing are needed to see the maximal therapeutic benefit.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The peak plasma concentrations for long-acting chlordiazepoxide are attained in several hours.</p>
        <p><bold>Distribution:</bold> Benzodiazepines exhibit widespread distribution throughout the body, preferring accumulation in lipid-rich regions, including the central nervous system (CNS). The plasma protein binding of chlordiazepoxide is high, approximately 96%.<xref ref-type="bibr" rid="article-41623.r9">[9]</xref></p>
        <p><bold>Metabolism:</bold> Chlordiazepoxide is metabolized by the liver microsomal pathway, first by hepatic oxidation and then glucuronidation.<xref ref-type="bibr" rid="article-41623.r10">[10]</xref></p>
        <p><bold>Elimination:</bold> The elimination half-life of this medication is 24 to 48 hours, and its excretion is via urine.<xref ref-type="bibr" rid="article-41623.r11">[11]</xref><xref ref-type="bibr" rid="article-41623.r12">[12]</xref></p>
      </sec>
      <sec id="article-41623.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Chlordiazepoxide is available as a capsule with&#x000a0;3 different strengths&#x02014;5 mg, 10 mg, and 25 mg&#x02014;for oral dosing and as an injectable with a concentration of 100 mg/5 mL. Typically available in gelatin capsule form, it is advised to store chlordiazepoxide between 68 &#x000b0;F&#x000a0;and 77&#x000b0;F (20 &#x000b0;C to 25 &#x000b0;C). The recommended approach is to administer the lowest effective dose, especially for pediatric patients aged 6 and older and geriatric patients. Injectable forms are not recommended for pediatric patients, and no data exist on their long-term effects.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Treatment of mild-to-moderate anxiety:</bold>&#x000a0;For the management of mild-to-moderate anxiety, the recommended oral dosage ranges from 15 to 40 mg/d, administered in 3 to 4 doses.</p>
        <p><bold>Treatment of severe anxiety:</bold>&#x000a0;For the treatment of severe anxiety, the oral dosage is typically prescribed in the range of 60 to 100 mg/d, distributed across 3 to 4 doses.</p>
        <p><bold>Treatment of acute-to-severe anxiety:</bold>&#x000a0;For the management of acute-to-severe anxiety using injectable chlordiazepoxide, the recommended initial dosage is 50 to 100 mg/d, followed by 25 to 50 mg/d administered 3 to 4 times if needed.</p>
        <p><bold>Treatment of alcohol withdrawal:</bold> For the treatment of alcohol withdrawal, the recommended oral dosage involves an initial administration of 50 to 100 mg/d, with the option to repeat after 2 hours as necessary until agitation or withdrawal symptoms are controlled. The dosage can be increased up to a maximum of 300 mg/d.</p>
        <p><bold>Treatment of preoperative apprehension and anxiety:</bold> For preoperative apprehension and anxiety, the oral dosage is 5 to 10 mg/d, administered in 3 to 4 doses preceding surgery. Alternatively, an injectable form may be used with 50 to 100 mg administered intramuscularly (IM) 1 hour before surgery.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The manufacturer's labeling does not include dosage adjustments; however, caution should be exercised when using chlordiazepoxide due to its hepatic metabolism.<xref ref-type="bibr" rid="article-41623.r10">[10]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;In patients with renal impairment, chlordiazepoxide is typically initiated orally at 10 to 20 mg daily, divided into 2 to 4 doses. Subsequent adjustments may be made based on individual responses and requirements. An initial dose of 25 to 50 mg is recommended for injectable forms.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;A risk of congenital malformations is associated with the administration of benzodiazepines, including chlordiazepoxide, during the first trimester of pregnancy. As the requirement for administering chlordiazepoxide is rarely urgent, it is advisable to refrain from their use during this crucial period. Healthcare professionals should be vigilant of the potential pregnancy status of women of childbearing potential at the initiation of therapy. Patients are advised that if they become pregnant during treatment or are planning pregnancy, it is recommended to discuss with their healthcare providers the appropriateness of discontinuing the drug.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;A&#x000a0;lack of available information precludes recommendations on chlordiazepoxide use during breastfeeding. Due to the potential accumulation of the drug and its metabolites in the breastfed infant, opting for an alternative medication is advisable, particularly when nursing a newborn or preterm infant. In cases where chlordiazepoxide is utilized, it is recommended to closely monitor the infant for signs such as sedation, poor feeding, and inadequate weight gain.<xref ref-type="bibr" rid="article-41623.r13">[13]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Due to the diverse response of pediatric patients to CNS-acting drugs, initiating therapy with chlordiazepoxide is recommended at the lowest effective dose and adjusting it as needed. Considering the limited clinical experience in pediatric patients aged 6 or younger, the use of chlordiazepoxide in this age group is not advisable. The suggested starting dosage for chlordiazepoxide is 5 mg, administered 2 to 4 times daily, with a potential increase to 10 mg, 2 to 3 times in specific pediatric cases.</p>
        <p><bold>Older patients:</bold>&#x000a0;The FDA-approved label recommends 5 mg of chlordiazepoxide, administered 2 to 4 times daily. As per the guidelines by the American Geriatric Society Beers Criteria, chlordiazepoxide is considered a potentially inappropriate medication for older adults due to its heightened sensitivity to benzodiazepines. Older patients are at an increased risk of experiencing cognitive impairment, falls, and fractures. However, the cautious use of chlordiazepoxide may be considered justifiable in some instances, including the management of seizure disorders, alcohol withdrawal, and periprocedural sedation.<xref ref-type="bibr" rid="article-41623.r14">[14]</xref></p>
      </sec>
      <sec id="article-41623.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Discontinuation of chlordiazepoxide due to adverse effects is uncommon. However, older and debilitated patients may experience certain common adverse effects. Most adverse effects associated with these medications are preventable by correct dosage adjustments. Common adverse effects include fatigue, sedation, depression, dizziness, ataxia, slurred speech, weakness, confusion, forgetfulness, nervousness, hyperexcitability, and pain at the injection site. Some of the rare adverse effects include mania, weight gain, hallucination, hypotension, skin eruptions, menstrual irregularity, dry mouth, and hypersalivation. Life-threatening adverse effects are blood dyscrasias, renal dysfunction, hepatic dysfunction, and respiratory depression, particularly when taken with CNS depressants in overdose. Hyperactive pediatric patients require monitoring for the paradoxical effect.<xref ref-type="bibr" rid="article-41623.r15">[15]</xref><xref ref-type="bibr" rid="article-41623.r16">[16]</xref>&#x000a0;Acute withdrawal of chlordiazepoxide can be associated with catatonia.<xref ref-type="bibr" rid="article-41623.r17">[17]</xref>&#x000a0;Chlordiazepoxide-associated delirium in alcohol withdrawal has been reported.<xref ref-type="bibr" rid="article-41623.r18">[18]</xref>&#x000a0;Benzodiazepines also increase the risk of angle closure glaucoma.<xref ref-type="bibr" rid="article-41623.r19">[19]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Strong drug interactions exist with the use of other CNS depressants or opioid medications. Respiratory depression, increased sedation, coma, and death can occur if taking these&#x000a0;2 drugs simultaneously. If it is necessary to use an opioid and chlordiazepoxide together, using the lowest possible dose with the shortest duration would help decrease the likelihood of respiratory depression. Clinicians should use this medication cautiously in people with pulmonary disease.<xref ref-type="bibr" rid="article-41623.r20">[20]</xref><xref ref-type="bibr" rid="article-41623.r21">[21]</xref></p>
        <p>Kratom has partial opioid agonist effects and is frequently subject to misuse. When kratom is used concurrently with benzodiazepines such as chlordiazepoxide, it elevates the risk of severe&#x000a0;CNS depression. Consequently, it is recommended to avoid this combination.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK532890/">[27][26]</ext-link></p>
      </sec>
      <sec id="article-41623.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>&#x000a0;<bold>Box Warnings</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>The simultaneous use of benzodiazepines and opioids can lead to profound sedation, respiratory depression, coma, and, in severe cases, fatalities. Prescribe these medications concomitantly only when alternative treatments are insufficient. Limit doses and treatment durations to the minimum necessary. Monitor for sedation and respiratory depression.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The use of benzodiazepines, including chlordiazepoxide, exposes individuals to the risk of misuse, abuse, and potential addiction, resulting in overdose or death. Benzodiazepine abuse and misuse often involve concurrent alcohol and illicit substances, contributing to a higher incidence of severe adverse outcomes. Before prescribing chlordiazepoxide and throughout treatment, evaluate each patient's susceptibility to abuse, misuse, and addiction.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prolonged use of benzodiazepines, including chlordiazepoxide, may lead to clinically significant physical dependence. The likelihood of dependence and withdrawal symptoms rises with extended treatment duration and higher daily doses. Abrupt cessation or rapid dose reduction of chlordiazepoxide following prolonged use can precipitate severe withdrawal reactions, posing a potential threat to life. To mitigate the risk of withdrawal reactions, employ a gradual taper when discontinuing chlordiazepoxide or adjusting the dosage.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An increased risk of suicidal ideation exists in a patient with major depressive disorder. It is not recommended for a pregnant patient or planning to get pregnant due to the potential risk of congenital anomalies, especially during the first trimester. Chlordiazepoxide may reduce the mental and physical abilities needed for the performance of some tasks, including driving a vehicle or operating heavy machinery. Similarly, it may diminish mental alertness in children.<xref ref-type="bibr" rid="article-41623.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Chlordiazepoxide is contraindicated with known hypersensitivity to chlordiazepoxide, other benzodiazepines, or its excipients.<xref ref-type="bibr" rid="article-41623.r23">[23]</xref></p>
      </sec>
      <sec id="article-41623.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Chlordiazepoxide is a schedule IV controlled drug.&#x000a0;A reported risk of dependence exists with long-term use.<xref ref-type="bibr" rid="article-41623.r24">[24]</xref>&#x000a0;Though no established cause-effect relationship exists, patients on anticoagulation should require monitoring for prothrombin time/international normalized ratio (PT/INR). Patients with porphyria also need monitoring because of possible porphyria exacerbation. Per clinical data, reports document paradoxical reactions such as acute rage, stimulation, and excitement in psychiatric and hyperactive pediatric patients on chlordiazepoxide therapy.<xref ref-type="bibr" rid="article-41623.r25">[25]</xref>&#x000a0;Prescribers and pharmacists must monitor treatment, provide patient education, and be vigilant in prescribing benzodiazepines such as chlordiazepoxide. The Prescription Drug Monitoring Program is capable of detecting potential misuse of chlordiazepoxide.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK532890/">[41]</ext-link></p>
      </sec>
      <sec id="article-41623.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>In cases of chlordiazepoxide overdose or toxicity, the patient may present with confusion, diminished reflexes, coma, or somnolence. Interventions include securing the airway and providing adequate intravenous fluid resuscitation. Patient respiration, blood pressure, and pulse&#x000a0;require regular monitoring.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Flumazenil, a specific benzodiazepine receptor antagonist used for a partial or complete reversal of the sedative property of benzodiazepines, is an option for treatment. Flumazenil works by competitively inhibiting the alpha-beta subunit GABA-binding site to exert its effect. After the administration of flumazenil, clinicians should monitor the patient for the risk of seizure associated with this medication, especially in patients with chronic benzodiazepine use.<xref ref-type="bibr" rid="article-41623.r26">[26]</xref></p>
      </sec>
      <sec id="article-41623.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Chlordiazepoxide, a prototype for the benzodiazepine compounds, has been in use since its development in 1960. Like other medications in this group, the use is worldwide, in and out of the hospital. Because of serious adverse effects, all healthcare professionals involved in prescribing, administering, and distributing this drug must educate patients on best-use practices. Patients should be informed about addiction potential, suicidal ideation in depression, respiratory depression, fetus malformation during pregnancy, sedation, fatigue, dizziness, ataxia, slurred speech, weakness, confusion, forgetfulness, nervousness, and hyperexcitability. Patients should be informed about life-threatening adverse effects if combined with opiates, alcohol, and other CNS-depressant medications. Furthermore, patients should understand the need to refrain from driving a car or operating heavy machinery.<xref ref-type="bibr" rid="article-41623.r27">[27]</xref><xref ref-type="bibr" rid="article-41623.r28">[28]</xref></p>
        <p>In a study, numerous investigations were identified that evaluated targeted pharmacist interventions for deprescribing benzodiazepines in older adults, with a limited emphasis on opioids. The EMPOWER brochure, directed at patients, emerged as a prevalent targeted intervention, complemented by electronic pharmacist communications, pharmacist-led deprescribing services, and multimodal interventions. Pharmacists, acknowledged as accessible and trusted healthcare professionals, are well-positioned for deprescribing. The outpatient focus on deprescribing opioids may be influenced by increased scrutiny in long-term care settings, emphasizing the importance of longitudinal care continuity. Despite inherent limitations in rapid reviews, this&#x000a0;study provides valuable insights into targeted pharmacist interventions for deprescribing in older adults, underscoring the pivotal role of pharmacists in facilitating safe and effective deprescribing practices.<xref ref-type="bibr" rid="article-41623.r29">[29]</xref></p>
        <p>After the clinician makes the therapeutic decision to prescribe chlordiazepoxide, the other interprofessional healthcare team members must also be involved in the therapy regimen. Nurses can counsel the patient, answer questions, monitor for signs of adverse effects, and verify patient compliance. The pharmacist should verify that the dosing is appropriate for the condition, check the medication profile for drug interactions, and be available to counsel the patient. Both pharmacy and nursing must have a clear communication channel to the prescriber. Psychiatrists should be consulted for severe anxiety disorders. An addiction medicine specialist should be consulted in chlordiazepoxide for acute alcohol withdrawal. Toxicologists and critical care&#x000a0;clinicians should be consulted for overdose. This type of interprofessional teamwork, including specialists, pharmacists, and nurses, ensures the optimal therapeutic benefit and minimal adverse events from chlordiazepoxide therapy, leading to better patient outcomes.</p>
      </sec>
      <sec id="article-41623.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41623&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41623">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41623/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41623">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41623.s11">
        <title>References</title>
        <ref id="article-41623.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.</article-title>
            <source>J Addict Med</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>14</volume>
            <issue>3S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-72</page-range>
            <pub-id pub-id-type="pmid">32511109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bijlsma</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Verdouw</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Garssen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Groenink</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The contribution of contextual fear in the anxiolytic effect of chlordiazepoxide in the fear-potentiated startle test.</article-title>
            <source>Behav Brain Res</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>353</volume>
            <fpage>57</fpage>
            <page-range>57-61</page-range>
            <pub-id pub-id-type="pmid">29969605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girish</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vikram Reddy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Pundarikaksha</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Vijendra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vasundara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Manjunatha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nagraj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shruthi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.</article-title>
            <source>Biomed J</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-80</page-range>
            <pub-id pub-id-type="pmid">27105601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fugger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mitschek</surname>
                <given-names>MMM</given-names>
              </name>
              <name>
                <surname>Kautzky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zohar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendlewicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Souery</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>41</volume>
            <fpage>70</fpage>
            <page-range>70-80</page-range>
            <pub-id pub-id-type="pmid">33046351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldschen-Ohm</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine Modulation of GABA<sub>A</sub> Receptors: A Mechanistic Perspective.</article-title>
            <source>Biomolecules</source>
            <year>2022</year>
            <month>Nov</month>
            <day>30</day>
            <volume>12</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">36551212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engin</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>GABA<sub>A</sub> receptor subtypes and benzodiazepine use, misuse, and abuse.</article-title>
            <source>Front Psychiatry</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1060949</fpage>
            <pub-id pub-id-type="pmid">36713896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griessner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasieka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;ssl</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaczanowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pliota</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kargl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaouane</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Strobelt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kreitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haubensak</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Central amygdala circuit dynamics underlying the benzodiazepine anxiolytic effect.</article-title>
            <source>Mol Psychiatry</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>534</fpage>
            <page-range>534-544</page-range>
            <pub-id pub-id-type="pmid">30504824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hambrecht-Wiedbusch</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Gauthier</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Baghdoyan</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Lydic</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine receptor agonists cause drug-specific and state-specific alterations in EEG power and acetylcholine release in rat pontine reticular formation.</article-title>
            <source>Sleep</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>909</fpage>
            <page-range>909-18</page-range>
            <pub-id pub-id-type="pmid">20614851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine pharmacology and central nervous system-mediated effects.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-23</page-range>
            <pub-id pub-id-type="pmid">23789008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Chlordiazepoxide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peppers</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease.</article-title>
            <source>Pharmacotherapy</source>
            <year>1996</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">8700792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masiulis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ucha&#x00144;ski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Serna Martin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Laverty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Malinauskas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zivanov</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pardon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steyaert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Aricescu</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>GABA<sub>A</sub> receptor signalling mechanisms revealed by structural pharmacology.</article-title>
            <source>Nature</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>565</volume>
            <issue>7740</issue>
            <fpage>454</fpage>
            <page-range>454-459</page-range>
            <pub-id pub-id-type="pmid">30602790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Chlordiazepoxide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baskin</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Esdale</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Is chlordiazepoxide the rational choice among benzodiazepines?</article-title>
            <source>Pharmacotherapy</source>
            <year>1982</year>
            <season>Mar-Apr</season>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-9</page-range>
            <pub-id pub-id-type="pmid">6152590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Askgaard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Potteg&#x000e5;rd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fink-Jensen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Benzodiazepines should still be first-line treatment for alcohol withdrawal].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2017</year>
            <month>Jan</month>
            <day>16</day>
            <volume>179</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28115043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaimes-Albornoz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ruiz de Pellon-Santamaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nizama-V&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Albajar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Serra-Mestres</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Catatonia in older adults: A systematic review.</article-title>
            <source>World J Psychiatry</source>
            <year>2022</year>
            <month>Feb</month>
            <day>19</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>348</fpage>
            <page-range>348-367</page-range>
            <pub-id pub-id-type="pmid">35317341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arabadjief</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gundumalla</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Menefee</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Moulana</surname>
                <given-names>NZ</given-names>
              </name>
              <name>
                <surname>El-Mallakh</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Chlordiazepoxide-induced delirium in a patient undergoing alcohol withdrawal: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2022</year>
            <month>Jul</month>
            <day>07</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>269</fpage>
            <pub-id pub-id-type="pmid">35799217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Namkoong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine Use and Risk of Acute Angle-Closure Glaucoma: A Population-Based Case-Crossover Study.</article-title>
            <source>Drug Saf</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>539</fpage>
            <page-range>539-547</page-range>
            <pub-id pub-id-type="pmid">32034700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Dorp</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Broens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Overdyk</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events.</article-title>
            <source>Ann Palliat Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>542</fpage>
            <page-range>542-557</page-range>
            <pub-id pub-id-type="pmid">32036672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;jehagen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e5;kansson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>174</volume>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">28315808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hohmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide.</article-title>
            <source>Phytother Res</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>1605</fpage>
            <page-range>1605-13</page-range>
            <pub-id pub-id-type="pmid">21031616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jawaro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pistun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dixit</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson Syndrome Associated With Chlordiazepoxide.</article-title>
            <source>J Pharm Technol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>82</fpage>
            <page-range>82-85</page-range>
            <pub-id pub-id-type="pmid">34860942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Votaw</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Geyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rieselbach</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of benzodiazepine misuse: A systematic review.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>200</volume>
            <fpage>95</fpage>
            <page-range>95-114</page-range>
            <pub-id pub-id-type="pmid">31121495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Champion</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Novais</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dorey</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Krolak-Salmon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lepetit</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Paradoxical reactions to benzodiazepines in the elderly].</article-title>
            <source>Geriatr Psychol Neuropsychiatr Vieil</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-312</page-range>
            <pub-id pub-id-type="pmid">34526288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives.</article-title>
            <source>J Clin Med</source>
            <year>2018</year>
            <month>Jan</month>
            <day>30</day>
            <volume>7</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29385731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasday</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Karch</surname>
                <given-names>FE</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine prescribing in a family medicine center.</article-title>
            <source>JAMA</source>
            <year>1981</year>
            <month>Sep</month>
            <day>18</day>
            <volume>246</volume>
            <issue>12</issue>
            <fpage>1321</fpage>
            <page-range>1321-5</page-range>
            <pub-id pub-id-type="pmid">7265426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kalava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Prescription of Controlled Substances: Benefits and Risks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30726003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41623.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niznik</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Armistead</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: A rapid review.</article-title>
            <source>Res Social Adm Pharm</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>2913</fpage>
            <page-range>2913-2921</page-range>
            <pub-id pub-id-type="pmid">34281786</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
